+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Therapeutic Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4774928
  • Report
  • April 2019
  • Region: Global
  • 112 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Agenus, Inc.
  • Argos Therapeutic Inc.
  • Celldex Therapeutic Inc.
  • Cytos Biotechnology AG
  • Dendreon Corp
  • GlaxoSmithKline
  • MORE
Market Overview

Global Therapeutic Vaccine market is expected to witness a CAGR of 12.63% during the forecast period. Certain factors that are driving the market growth include favorable government funding for vaccine development, rising prevalence of diseases, and an increase in R&D expenditure by the companies.

With the increased awareness of the potential value of vaccination, not only in the developed regions of the world, but also in the developing and in the under-developed regions, major governmental and humanitarian organizations have taken up an active interest in curbing the vaccine-preventable diseases and in vaccinating the maximum number of infants and adults as possible. This has led to the adoption of new production and supply strategies and the formation of what is now called the donor market, which accounts for the biggest market globally for vaccines, in terms of dosage. To achieve the full potential of science and technology and to prevent the onset of diseases in the population (especially children), various regional Governments have established agreements and partnerships with several organizations to initiate/ improve the already existing R&D schemes to prevent any future onset disease outbreak.

However, there is one drawback in this scenario. Similar to drug production, R&D of vaccine takes a long period of time and it requires huge investments. Vaccines have to undergo clinical trials before they obtain approval for commercial release. At each stage of the clinical trial, the majority of the vaccines are rejected. By the time the final product is approved for commercial use, there is a humongous capital spent on the R&D process of vaccine development. This huge capital expenditure has an indirect effect on the final pricing of the product. The product becomes expensive in certain cases, which is not affordable to a major chunk of the population, especially in the third world regions where the per capita income is significantly lower.

Scope of the Report

A therapeutic vaccine is the one in which the vaccine is applied after infection occurs, in order to induce antiviral immunity to alter the course of the disease. In other words, therapeutic vaccines help teach the body how to do a better job of protecting itself.

Key Market Trends

Auto-Immune Disease Vaccines is Expected to Hold Significant Market Share

Autoimmune diseases are those, which occur when the body’s immune system attacks and destroys healthy tissues of the body by mistake. An autoimmune disorder can lead to the growth of a tumor, damage healthy tissues and cause changes in the function of a specific organ. Autoimmune diseases can affect blood vessels, connective tissues, endocrine glands, joints, muscles, red blood cells, skin, etc. Autoimmune diseases are among the top ten leading causes for death among women in all age groups, spanning to those up to 65 years. A substantial minority of the population suffers from these diseases, which are attenuating, chronic and fatal. The development of vaccines for different types of autoimmune diseases is underway.

North America Dominates the Market and Expected to do Same in the Forecast Period

The United States is the largest market in North America, which accounts for about 78% of the total market volume. Canadian and Mexican markets have high growth potentials and the US market is focused on the invention and development of new vaccines. The demand for better and more efficient vaccines is expected to increase, which may reduce the shortfall of vaccines during disease outbreaks. For example, the demand for the measles vaccines has increased drastically, due to the worst measles outbreak in North America over the past 15 years.

Competitive Landscape

The global Therapeutic Vaccine market is highly competitive and consists of a number of major players. Companies like Agenus, Inc., Argos Therapeutic Inc., Celldex Therapeutic Inc., Cytos Biotechnology AG, Dendreon Corp, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Vaccinogen, Inc., among others, hold the substantial market share in the Therapeutic Vaccine market.
Note: Product cover images may vary from those shown
2 of 4


  • Agenus, Inc.
  • Argos Therapeutic Inc.
  • Celldex Therapeutic Inc.
  • Cytos Biotechnology AG
  • Dendreon Corp
  • GlaxoSmithKline
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Favorable Government Funding For Vaccine Development
4.2.2 Rising Prevalence of Diseases
4.2.3 Increase in R&D Expenditure by the Companies
4.3 Market Restraints
4.3.1 Huge Capital Expenditures
4.3.2 Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Products
5.1.1 Auto Immune Disease Vaccines
5.1.2 Neurological Disease Vaccines
5.1.3 Cancer Vaccines
5.1.4 Infectious Disease Vaccines
5.1.5 Others
5.2 Technology
5.2.1 Allogeneic Vaccine
5.2.2 Autologous Vaccine
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Agenus, Inc.
6.1.2 Argos Therapeutic Inc.
6.1.3 Celldex Therapeutic Inc.
6.1.4 Cytos Biotechnology AG
6.1.5 Dendreon Corp
6.1.6 GlaxoSmithKline
6.1.7 Merck & Co.
6.1.8 Novartis
6.1.9 Pfizer
6.1.10 Vaccinogen, Inc.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Agenus, Inc.
  • Argos Therapeutic Inc.
  • Celldex Therapeutic Inc.
  • Cytos Biotechnology AG
  • Dendreon Corp
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • Pfizer
  • Vaccinogen, Inc.
Note: Product cover images may vary from those shown